Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0CXFTH)
| ADC Name |
Serclutamab talirine
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
serclutamab talirine; ABBV-321; Ser-T
Click to Show/Hide
|
|||||
| Organization |
AbbVie (Top20 MNC) (Originator);Life Science Pharmaceuticals (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Serclutamab
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
SGD-1882
|
Payload Info | ||||
| Payload Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
talirine
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Patient-derived Xenograft Model
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility requires ECOG 0-1 patients with progressive EGFR+ tumors (GBM/CRC/HNSCC/NSCLC/others) refractory to prior therapies (≤3 cytotoxic lines), measurable disease, and ≥12-week life expectancy, excluding those with uncontrolled CNS metastases, cardiac dysfunction (NYHA III-IV/EF<40%), active infections (CTCAE≥G3), recent major surgery (21 days), or significant effusions/keratitis. Washout periods apply for prior therapies (21 days for most, 5 half-lives for targeted agents).
Click to Show/Hide
|
||||
| Administration Dosage |
ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03234712 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) | ||||
| Primary Endpoint |
The primary pharmacokinetic endpoints evaluate ABBV-321 exposure (AUCt, AUC), peak concentration (Cmax), time to peak (Tmax), elimination characteristics (beta, t1/2) over 78 days, along with dose-escalation outcomes (MTD, RPTD) during the first 28-day cycle in EGFR-overexpressing solid tumor patients.
|
||||
| Other Endpoint |
Secondary efficacy measures assess long-term outcomes (PFS, DOR, DCR, TTP, OS up to 5 years) using RECIST 1.1/RANO criteria, QTcF interval changes through 61 days, and ORR in both solid tumors and glioblastoma populations.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Partial Response (PR) | 4.17% | High EGFR expression (EGFR+++) | ||
| Patients Enrolled |
Advanced, histologically confirmed solid tumors associated with EGFR overexpression (centralized testing).
|
||||
| Administration Dosage |
Ser-T intravenously once every 4 weeks (Q4W; 5-50 ug/kg) in the dose-escalation phase.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03234712 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR). | ||||
| Primary Endpoint |
One patient was PR (N=1/24, 4.17%), 6 patients was SD (N=6/24,25.00%). Median DOR (CR + PR + SD)=6.40 months (95% CI 3.0not reached). The median PFS=1.8 months (95% CI 1.3-5.8), median OS=7.10 months (95% CI: 4.1-12.3).
|
||||
| Other Endpoint |
Ser-T RP2D regimen=25 ug/kg Q4W.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Partial Response (PR) | 4.20% | High EGFR expression (EGFR+++) | ||
| Patients Enrolled |
Advanced, histologically confirmed solid tumors associated with EGFR overexpression (centralized testing).
|
||||
| Administration Dosage |
Ser-T intravenously once every 4 weeks (Q4W; 5-50 ug/kg) in the dose-escalation phase.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03234712 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR). | ||||
| Primary Endpoint |
Responses included 1 partial response (PR), 6 stable disease (SD), 14 progressive disease (PD); 3 patients were not evaluable for response. Median duration of clinical benefit (complete response + PR + SD) was 6.40 months (95% CI: 3.00-not reached).
|
||||
| Other Endpoint |
The median PFS was 1.80 months (95% CI: 1.30-5.80) and the median OS was 7.10 months (95% CI: 4.10-12.30).
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03234712 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR). | ||||
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 34% | High EGFR expression (EGFR+++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO199) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 40% | Low EGFR expression (EGFR+) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO199) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 76% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,demonstrated with ABBV-321 dosed at 0.15 mg/kg 2 every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing malignant mesothelioma PDX model (PDX: 1174) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.57% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO207) | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.20% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO199) | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 91.60% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO207) | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.70% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO207) | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.80% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression, administered at 0.5 mg/kg on a Q7D 6 regimen.
|
||||
| In Vivo Model | EGFR-expressing colorectal adenocarcinoma PDX model (PDX: LoVo) | ||||
| Experiment 9 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.40% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO207) | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.20% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO199) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 52.40% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.0125 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 55.30% | Low EGFR expression (EGFR+) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of lung squamous cell carcinoma cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 70.60% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.025 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 73.80% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing A-253 CDX model | ||||
| In Vitro Model | Submandibular gland squamous cell carcinoma | A-253 cells | CVCL_1060 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 81.10% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.3 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing A-253 CDX model | ||||
| In Vitro Model | Submandibular gland squamous cell carcinoma | A-253 cells | CVCL_1060 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.80% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.80% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.05 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 83.10% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing FaDu CDX model | ||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.90% | Low EGFR expression (EGFR+) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,administered 0.4 mg/kg,at every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing HCT 116 CDX model | ||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.90% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing HCT 116 CDX model | ||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 91.80% | Negative EGFR expression (EGFR-) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.3 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing FaDu CDX model | ||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | High EGFR expression (EGFR+++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Low EGFR expression (EGFR+) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Low EGFR expression (EGFR+) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of lung squamous cell carcinoma cell with EGFR expression,a single dose of 0.3 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
15 pM
|
|||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.23 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | U-87 MGvIII cells | CVCL_0022 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.7 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | LoVo cells | CVCL_0399 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.7 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | U-251MG cells | CVCL_0021 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.1 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SK-CO-1 cells | CVCL_0626 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.4 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | SF268 cells | CVCL_1689 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.5 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 9 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.5 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | M059K cells | CVCL_0401 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.8 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW403 cells | CVCL_0545 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.9 nM | High EGFR expression (EGFR+++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Primitive neuroectodermal tumor | PFSK-1 cells | CVCL_1642 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.5 nM | High EGFR expression (EGFR+++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Gliosarcoma | SF539 cells | CVCL_1691 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.6 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 201 cells | CVCL_1987 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.8 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | M059J cells | CVCL_0400 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.3 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 205 cells | CVCL_0218 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.7 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | SNB-19 cells | CVCL_0535 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.3 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW620 cells | CVCL_0547 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.6 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW1116 cells | CVCL_0544 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.6 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.7 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon carcinoma | RKO cells | CVCL_0504 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.8 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Rectal adenocarcinoma | SW1463 cells | CVCL_1718 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.8 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Anaplastic astrocytoma | CHLA-03-AA cells | CVCL_U616 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.5 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | WiDr cells | CVCL_2760 | ||
| Experiment 24 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 8 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
| Experiment 25 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 8.4 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | LN-18 cells | CVCL_0392 | ||
| Experiment 26 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 9 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | DLD-1 cells | CVCL_0248 | ||
| Experiment 27 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 9.5 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Cecum adenocarcinoma | LS1034 cells | CVCL_1382 | ||
| Experiment 28 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 10.6 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | SNB-75 cells | CVCL_1706 | ||
| Experiment 29 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 11.8 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | T84 cells | CVCL_0555 | ||
| Experiment 30 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 12 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
| Experiment 31 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 13.9 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | Caco-2 cells | CVCL_0025 | ||
| Experiment 32 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 14.5 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | T98G cells | CVCL_0556 | ||
| Experiment 33 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 16.1 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | U-138MG cells | CVCL_0020 | ||
| Experiment 34 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 17.6 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 320DM cells | CVCL_0219 | ||
| Experiment 35 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 18 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Anaplastic astrocytoma | DBTRG-05MG cells | CVCL_1169 | ||
| Experiment 36 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
23.2 nM
|
|||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | A-172 cells | CVCL_0131 | ||
| Experiment 37 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 24.9 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 320HSR cells | CVCL_0220 | ||
| Experiment 38 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 28.4 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | HCT 15 cells | CVCL_0292 | ||
References